Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C

@article{Smith2011TelaprevirAN,
  title={Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C},
  author={Lisa S. Smith and Michael Nelson and Sagar Naik and Joanna Woten},
  journal={Annals of Pharmacotherapy},
  year={2011},
  volume={45},
  pages={639 - 648}
}
Objective: To review the use of telaprevir for the treatment of chronic hepatitis C. Data Sources: Clinical studies were identified through MEDLINE (1966-January 2011), bibliographies of articles, clinicaltrials.gov, and fda.gov, using key words VX-950, telaprevir, and chronic hepatitis C. Study Selection and Data Extraction: Phase 1, 2, and 3 human and animal studies describing the pharmacology, pharmacokinetics, efficacy, and safety of telaprevir were identified. Additional articles were… 

Figures and Tables from this paper

Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.

TLDR
Sofosbuvir has a favorable safety and tolerability profile, making it a recommended first-line agent for chronic HCV infection, and it is not recommended as monotherapy because of lower sustained virological response (SVR) rates in clinical studies.

Safety of Telaprevir for Chronic Hepatitis C Virus Infection

TLDR
A meta-analysis raises safety concerns about the potential for an increased risk of serious adverse events associated with the use of telaprevir among patients with chronic hepatitis C virus infection, and cautious use of telecommunications is warranted.

Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.

TLDR
A meta-analysis raises safety concerns about the potential for an increased risk of serious adverse events associated with the use of telaprevir among patients with chronic hepatitis C virus infection, and cautious use oftelaprevIR is warranted.

Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions

TLDR
Future studies should focus on the pharmacokinetics/pharmacodynamics of telaprevir in special populations or patients with concomitant conditions that will likely co-exist with HCV infection, with an emphasis on establishing pharmacokinetic–pharmacodynamic relationships.

Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.

TLDR
The overall SVR rate in cirrhotic patients treated with standard of care therapy is 33.3%, but lower in cases affected by genotypes 1 and 4 (21.6%) which makes them a priority regarding the development of more potent drugs for effective treatment.

Characterization of Healthy Donor-Derived T-Cell Responses Specific to Telaprevir Diastereomers

TLDR
Data show the propensity of both R- and S-forms of telaprevir to generate skin-homing cytotoxic T-cells that may induce the adverse reactions observed in human patients.

Characterisation of healthy donor-derived T-cell responses specific to telaprevir

TLDR
Data show the propensity of both Rand S-forms of telaprevir to generate skin-homing cytotoxic T-cells that may induce the adverse reactions observed in human patients.

Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population

TLDR
This chapter provides a detail review of pharmacokinetic and pharmacodynamic parameters of antiviral agents utilized to treat select viral infections in patients undergoing transplantation.

Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer

TLDR
This review will explore the pathways by which CXCL10 is produced by hepatocytes during HCV infection, its effects on resident and infiltrating immune cells, and how deregulation of these cell populations within the liver may lead to chronic liver inflammation.

Characterisation of drug-specific T-cell responses in hypersensitive patients and healthy donors

TLDR
The results define in immunological, chemical and quantitative terms the drug immune receptor interactions that can drive a T-cell response for β-lactam antibiotics and piperacillin.

References

SHOWING 1-10 OF 47 REFERENCES

The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus

TLDR
Telaprevir has an acceptable pharmacokinetic profile and seems to be a potent antiviral drug against HCV, although, owing to a low genetic barrier, resistant variants emerge within a few days when used in monotherapy, thereby decreasing its efficacy.

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

TLDR
Telaprevir (VX-950) is the protease inhibitor in the most advanced phase of clinical testing and possible use of this drug in combination with other drugs for the treatment of HCV infection.

Telaprevir: a new hope in the treatment of chronic hepatitis C?

TLDR
Perhaps the most advanced HCV protease inhibitor in clinical development is telaprevir, which has been shown to improve treatment outcomes when combined with PEG-IFN-α/RBV in genotype 1 infection, and is currently undergoing phase 3 study.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

TLDR
Resistant HCV isolates are selected rapidly during therapy with the highly active protease inhibitor telaprevir, and changes in the frequency of mutations after the end of dosing showed an inverse relationship between in vivo viral fitness and resistance.

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

BackgroundThe inhibitor telaprevir (VX-950) of the hepatitis C virus (HCV) protease NS3-4A has been tested in a recent phase 1b clinical trial in patients infected with HCV genotype 1. This trial

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

  • F. SuzukiYoshiyuki Suzuki H. Kumada
  • Medicine, Biology
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2010

Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.

TLDR
The remarkable progress of these drug candidates are related to recent evidence that suggests HCV might depend on NS3.4A protease to subvert multiple innate cellular defense mechanisms.

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

TLDR
Results indicate that the HCV replicon presents a higher barrier to the selection of resistance to nucleoside inhibitors than to nonnucleoside or protease inhibitors, which could have a clear clinical benefit through the delay of resistance emergence.

Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C

Telaprevir (VX‐950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RNA levels in a prior clinical study. The present study evaluated viral kinetics